Raysa Morales-Demori MD, FAAP


  • Texas Medical Center


Critical Care

Phone: 832-826-6230

Contact Information

6651 Main Street
MC E1420
Houston, TX 77030
United States
Texas US

Assistant Professor of Pediatrics, Section of Critical Care Medicine

Baylor College of Medicine


School Education Degree Year
Baylor College of Medicine fellowship Pediatric Critical Care 2019
Baylor College of Medicine fellowship Pediatric Cardiology 2017
Children’s Hospital of the University of Illinois – College of Medicine residency Pediatrics 2014
Universidad Central de Venezuela – Escuela de Medicina Luis Razetti medical school Doctor of Medicine 2008


The journey that a patient with congenital or acquired heart disease takes is complex and unique. I am humbled to share that journey with you by providing safe and high-quality care. I believe that family/primary care takers play a key role in patient’s clinical progress, for that reason, I make sure that each family understands their child’s condition and listen to care taker’s input.

Clinical Interests:

My clinical interest in the management of pulmonary hypertension and/or right ventricular failure in patients with congenital heart disease.

Research Interests:

Pulmonary hypertension; Pediatric Heart failure, Population studies in pediatric cardiology 


Organization Name Role
American Academy of Pediatrics Member
American Academy of Pediatrics Member Society of Critical Care Medicine Member
Pediatric Cardiac Intensive Care Society Member

Selected Publications

Morales-Demori R. “Congenital heart disease and cardiac procedural outcomes in patients with trisomy 21 and Turner syndrome”. Congenit Heart Dis 2017 Dec;12(6):820-7.

Morales-Demori R, Jamil O, Serratto M. “Trend of Endurance Level Among Healthy Inner-City Children and Adolescents Over Three Decades”. Pediatric Cardiology 2017 Jan;38(1):123-7.

Rangel, MO., Morales Demori, R., Voll, ST., Wassouf, M., Dick, R., Doukky, R. "Severe chronic kidney disease as a predictor of benefit from aminophylline administration in patients undergoing regadenoson stress myocardial perfusion imaging: A substudy of the ASSUAGE and ASSUAGE-CKD trials". J Nucl Cardiol 2015, Oct; 5(22):1008-18.

Ballany, W., Mansour, K., Morales Demori, R., Al-Amoodi, M., Doukky, R. The impact of regimented aminophylline use on extracardiac radioisotope activity in patients undergoing regadenoson stress SPECT myocardial perfusion imaging: A substudy of the ASSUAGE trial. J Nucl Cardiol 2014, Jun; 21(3):496-502.

Doukky, R., Rangel, MO., Wassouf, M., Dick, R., Alqaid, A., Morales Demori, R. The Safety and Tolerability of Regadenoson in Patients with End-Stage Renal Disease: The First Prospective Evaluation. Journal of Nuclear Cardiology 2013 Apr;20(2):205-13.

Rangel, MO., Morales Demori, R., Doukky, R. Age and Gender as Predictors of Benefit From Aminophylline Administration in Patients Undergoing Regadenoson Stress Myocardial Perfusion Imaging: A Substudy of the ASSUAGE Trial. Am J Ther 2013. Nov-Dec;20(6):622-9.

Doukky, R., Morales Demori, R., Jain, S., Kiriakos, R., Mwansa, V., Calvin, JE. Attenuation of The Side Effect Profile of Regadenoson: A Randomized Double-Blind Placebo-Controlled Study with Aminophylline in Patients Undergoing Myocardial Perfusion Imaging. “THE ASSUAGE TRIAL". Journal of Nuclear Cardiology. 2012 Jun; 19(3):448-57.